СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
LDL receptor plays a key role in the metabolism of LDL cholesterol. It have been shown that proprotein convertase subtlisin/kexin type 9 is essential for post-transcriptional regulatation of the cell surface expression of the LDL receptor by participating in its degradation. The data from large epid...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2013-12-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/243 |
| Summary: | LDL receptor plays a key role in the metabolism of LDL cholesterol. It have been shown that proprotein convertase subtlisin/kexin type 9 is essential for post-transcriptional regulatation of the cell surface expression of the LDL receptor by participating in its degradation. The data from large epidemiological studies indicate that persons with the loss-of-function mutations of PCSK9 have lower LDL level and CHD morbidity. Thus the development of biotechnical/pharmacological agents able to block PCSK9 can be the new option for treatment of patients with severe hyperlipidemia. Currently effectiveness of this approach is studied in large international randomized clinical trials. |
|---|---|
| ISSN: | 2226-6704 2411-6564 |